Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations.
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · 2 tiers
Human trial
1
Animal model
2
03
What the studies show
Animal model
Kaninchen
Schoenenberger GA, Monnier M 1977
EEG changes with increased delta activity after intravenous administration in rabbits originally reported
What does NOT follow: Original finding of the discovering group; later replication attempts in other animal models and in humans yielded heterogeneous results.
Human trial
Mensch
Shortening of sleep-onset latency reported in a small clinical pilot study in patients with chronic insomnia
What does NOT follow: Small sample (<30), no blinding against active comparator. No systematic Cochrane review of DSIP exists — the evidence base is considered insufficient.
Animal model
Maus
Analgesic effects documented in tail-flick and hot-plate tests in mice
What does NOT follow: Standard animal models for analgesia; clinical relevance in humans not established.
04
Where studies disagree
Open question
Does DSIP actually induce delta sleep in humans?
POSITION A
The Schoenenberger-Monnier group and some Soviet-Russian studies reported EEG changes toward delta activity.
POSITION B
Several Western replication attempts in the 1990s could not consistently reproduce the effect. Sleep medicine has not established DSIP as a therapeutic option.
CURRENT STATE · The scientific community today considers DSIP historically interesting but therapeutically not established. The substance is practically no longer studied in modern sleep medicine.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.1 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Intravenous
Administered intravenously in the original Swiss research studies — compatible with the very short half-life.
Subcutaneous
In later Russian studies also subcutaneous; black-market use predominantly follows this route.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Anecdotal
Safety profile inadequately documented
Evidence is limited to small studies from the 1980s-2000s without systematic pharmacovigilance.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
In bio-hacking forums DSIP is described as a 'gentle sleep modulator'.
common in nootropic communities
Not supported by studies: This claim rests on self-reports and the original animal-experiment hypothesis. Controlled efficacy in humans has never been confirmed in a large RCT. The extremely short half-life additionally calls duration-of-effect assumptions into question.
11
Legal status by country
Country
Status
Note
Checked
United States
Unapproved
No FDA approval. Sale as a 'research chemical' is not legally covered.
2026-05-22
Germany
Unapproved
No EMA approval. Not marketable as a medicine.
2026-05-22
RU
Research only
Commonly used in Russian research; no broad medicines approval comparable to Western standards.
2026-05-22
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Animal model
Schoenenberger GA, Monnier M · 1977
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide